Ocular Blood Flow Imaging for Glaucoma Assessment

The goal of this clinical trial is to investigate the use of an FDA-cleared retinal blood flow imaging instrument called the XyCAM RI and XyCAM FC (Vasoptic Medical, Inc., Columbia, MD) in glaucoma management.The main question it aims to answer are:Can the investigators use blood flow to discriminate between eyes with early-stage glaucoma and variable-matched controls?Can the investigators validate that the XyCAM FC simultaneously captures both stereo fundus photography and ocular blood flow monitoring?Participants will bemeasured for their blood pressure, heart rate, height, and weightdilated with tropicamideimaged using the XyCAM RI, fundus photography, optical coherence tomography, and standard automated perimetryimaged using the XyCAM RI while inhaling 100% oxygen through a mask

Inclusion Criteria:Age 18 and older with binocular visionAble to provide informed consentPatient is a healthy control OR is recommended for glaucoma assessment OR diagnosed with moderate to severe glaucoma in at least one eye as determined by Hodapp Anderson CriteriaExclusion Criteria:The subject has significant media opacity (e.g., a visually significant cataract or significant corneal scar)The subject has previous ocular surgery other than uncomplicated cataract extraction, laser trabeculoplasty (ALT or SLT), or YAG capsulotomyThe subject has prior ocular disease other than glaucomaThe subject has anatomically narrow angles or a prior adverse reaction to administration of Tropicamide or fluorescein dyeThe subject has more than 15 diopters of refractive errorThe subject is a female who is pregnant or nursingThe subject has diabetes mellitus